Table 1.
Patient, disease, and transplant characteristics
| Variable | Tac/MTX (N = 49) N (%) |
Tac/mini-MTX/MMF (N = 47) N (%) |
P value |
|---|---|---|---|
| Age at transplant, y | |||
| Median (range) | 47 (5-59) | 45 (2-62) | .47 |
| Sex | |||
| Male | 21 (42.9) | 30 (63.8) | .04 |
| Female | 28 (57.1) | 17 (36.2) | |
| Race | |||
| White | 48 (98.0) | 47 (100.0) | .32 |
| Black | 1 (2.0) | 0 (0.0) | |
| HCT-CI | |||
| Low | 4 (8.2) | 8 (17) | .30 |
| Intermediate | 19 (38.8) | 20 (42.6) | |
| High | 26 (53.1) | 19 (40.4) | |
| Diagnosis | |||
| AML | 30 (61.2) | 19 (40.4) | .14 |
| ALL | 6 (12.2) | 8 (17.0) | |
| MDS | 3 (6.1) | 8 (17.0) | |
| CML | 3 (6.1) | 6 (12.8) | |
| MPN | 2 (4.1) | 4 (8.5) | |
| NHL | 2 (4.1) | 2 (4.3) | |
| Other (acute leukemia) | 3 (6.1) | 0 (0.0) | |
| Disease risk index | |||
| Low | 9 (18.4) | 14 (29.8) | .46 |
| Intermediate | 27 (55.1) | 22 (46.8) | |
| High | 13 (26.5) | 11 (23.4) | |
| Donor | |||
| Matched unrelated | 38 (77.6) | 34 (72.3) | .56 |
| Matched sibling | 11 (22.4) | 13 (27.7) | |
| Conditioning | |||
| Bu/Cy | 40 (81.6) | 39 (83.0) | .54 |
| TBI/VP | 9 (18.4) | 7 (14.9) | |
| Cy/TBI | 0 (0.0) | 1 (2.1) | |
| Graft source | |||
| BM | 44 (89.8) | 39 (83.0) | .33 |
| Peripheral blood | 5 (10.2) | 8 (17.0) | |
| Donor-recipient sex | |||
| From F to M | 5 (10.4) | 8 (17.8) | .10 |
| Baseline CMV status | |||
| D+/R+ | 13 (26.5) | 6 (12.8) | .17 |
| D+/R– | 4 (8.2) | 5 910.6) | |
| D–/R+ | 24 (49.0) | 21 (44.7) | |
| D–/R– | 8(16.3) | 15 (31.9) | |
| MTX doses | |||
| 2 | 1 (2.0) | 0 (0.0) | < .001 |
| 3 | 13 (26.5) | 47 (100.0) | |
| 4 | 35 (71.4) | -- |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Bu/Cy, busulfan and Cy; CML, chronic myeloid leukemia; CMV, cytomegalovirus; D, donor; F, female; HCT-CI, HCT comorbidity index; M, male; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; R, recipient; TBI/VP, TBI with etoposide.